Skip to main content
Olympus Corporation (OCPNF)
OTCMKTS · Delayed Price · Currency is USD
12.65
-0.11 (-0.83%)
At close: Apr 28, 2025

Revenue by Product

Fiscal year is April - March.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
 Mar '24 Mar '23 Mar '22 Mar '21
Total Medical Solutions Division
Log In
Log In
Log In
Log In
Total Medical Solutions Division Growth
Log In
Log In
Log In
Log In
Scientific Solutions Division
Log In
Log In
Log In
Log In
Scientific Solutions Division Growth
Log In
Log In
Log In
Log In
Other Division Revenue (Pre-FY2025 Reporting)
Log In
Log In
Log In
Log In
Other Division Revenue (Pre-FY2025 Reporting) Growth
Log In
Log In
Log In
Log In
Endoscopic Solutions Division
Log In
Log In
Log In
Log In
Endoscopic Solutions Division Growth
Log In
Log In
Log In
Log In
Therapeutic Solutions Division
Log In
Log In
Log In
Log In
Therapeutic Solutions Division Growth
Log In
Log In
Log In
Log In
Other Division Revenue (Post-FY2024 Reporting)
Log In
Log In
Log In
Log In

EBIT by Product

Fiscal year is April - March.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
 Mar '24 Mar '23 Mar '22 Mar '21
Total Medical Solutions Division Operating Profit
Log In
Log In
Log In
Log In
Total Medical Solutions Division Operating Profit Growth
Log In
Log In
Log In
Log In
Scientific Solutions Division Operating Profit
Log In
Log In
Log In
Log In
Scientific Solutions Division Operating Profit Growth
Log In
Log In
Log In
Log In
Other Division Operating Profit (Pre-FY2025 Reporting)
Log In
Log In
Log In
Log In
Other Division Operating Profit (Pre-FY2025 Reporting) Growth
Log In
Log In
Log In
Log In
Eliminations from Division Operating Profit
Log In
Log In
Log In
Log In
Eliminations from Division Operating Profit Growth
Log In
Log In
Log In
Log In
Endoscopic Solutions Division Operating Profit
Log In
Log In
Log In
Log In
Endoscopic Solutions Division Operating Profit Growth
Log In
Log In
Log In
Log In
Therapeutic Solutions Division Operating Profit
Log In
Log In
Log In
Log In
Therapeutic Solutions Division Operating Profit Growth
Log In
Log In
Log In
Log In
Other Division Operating Profit (Post-FY2024 Reporting)
Log In
Log In
Log In
Log In

Revenue by Geography

Fiscal year is April - March.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
 Mar '24 Mar '23 Mar '22 Mar '21
Japan
Log In
Log In
Log In
Log In
Japan Growth
Log In
Log In
Log In
Log In
North America
Log In
Log In
Log In
Log In
North America Growth
Log In
Log In
Log In
Log In
Europe
Log In
Log In
Log In
Log In
Europe Growth
Log In
Log In
Log In
Log In
Asia and Oceania Revenue (Pre-FY2020 Reporting)
Log In
Log In
Log In
Log In
Asia and Oceania Revenue (Pre-FY2020 Reporting) Growth
Log In
Log In
Log In
Log In
Other Countries
Log In
Log In
Log In
Log In
Other Countries Growth
Log In
Log In
Log In
Log In
China
Log In
Log In
Log In
Log In
China Growth
Log In
Log In
Log In
Log In
Asia and Oceania Revenue (Post-FY2019 Reporting)
Log In
Log In
Log In
Log In
Asia and Oceania Revenue (Post-FY2019 Reporting) Growth
Log In
Log In
Log In
Log In

Other

Fiscal year is April - March.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
 Mar '24 Mar '23 Mar '22 Mar '21
Company's Total Revenue Growth Rate After FX Adjustment
Log In
Log In
Log In
Log In
Total Endoscopic Solutions Division (ESD) Revenue Growth Rate After FX Adjustment
Log In
Log In
Log In
Log In
Total Therapeutic Solutions Division (TSD) Revenue Growth Rate After FX Adjustment
Log In
Log In
Log In
Log In
ESD - GI Endoscopy Revenue Growth Rate After FX Adjustment
Log In
Log In
Log In
Log In
ESD - Surgical Endoscopy Revenue Growth Rate After FX Adjustment
Log In
Log In
Log In
Log In
ESD - Medical Service Revenue Growth Rate After FX Adjustment
Log In
Log In
Log In
Log In
TSD - GI EndoTherapy Revenue Growth Rate After FX Adjustment
Log In
Log In
Log In
Log In
TSD - Urology Revenue Growth Rate After FX Adjustment
Log In
Log In
Log In
Log In
TSD - Respiratory Revenue Growth Rate After FX Adjustment
Log In
Log In
Log In
Log In
TSD - Other Therapeutic Areas Revenue Growth Rate After FX Adjustment
Log In
Log In
Log In
Log In